Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir

Jesús Domínguez-Rojas(Hospital Clínic de Barcelona), Estebán Martínez(Instituto de Salud Carlos III), Celia Miralles, Anna Cruceta(Universitat de Barcelona), Víctor Asensi(Baylor College of Medicine), Arkaitz Imaz(Bellvitge University Hospital), Mireia Arnedo(Escuela Nacional de Sanidad), Montserrat Loncà(Universitat Pompeu Fabra), Marta Montero, Ignacio Pérez(Apple (Israel)), Peré Domingo(Hospital de Sant Pau), Joan Fontdevila(Hospital Clínic de Barcelona), Luis del Río(Bellvitge University Hospital), JM Gatell(Hospital Clínic de Barcelona), Vicente Estrada(Instituto de Salud Carlos III)
HIV Medicine
September 10, 2015
10.1111/hiv.12314
Cited by 4

Related Papers

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
|JAMA|2016|1.4k
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
|The Lancet|2019|1k
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728
Pitavastatin to Prevent Cardiovascular Disease in HIV Infection
|New England Journal of Medicine|2023|476
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
|The Lancet|2006|343